Your browser is no longer supported. Please, upgrade your browser.
SLDB Solid Biosciences Inc. daily Stock Chart
Solid Biosciences Inc.
Index- P/E- EPS (ttm)-2.65 Insider Own4.00% Shs Outstand48.06M Perf Week-6.05%
Market Cap138.15M Forward P/E- EPS next Y-1.05 Insider Trans0.00% Shs Float25.56M Perf Month18.47%
Income-114.30M PEG- EPS next Q-0.50 Inst Own57.60% Short Float3.11% Perf Quarter-10.61%
Sales- P/S- EPS this Y-29.40% Inst Trans-0.88% Short Ratio2.34 Perf Half Y-27.16%
Book/sh1.17 P/B2.52 EPS next Y27.30% ROA-113.00% Target Price5.17 Perf Year-43.38%
Cash/sh1.14 P/C2.58 EPS next 5Y- ROE-142.20% 52W Range1.96 - 13.58 Perf YTD-33.71%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-78.28% Beta-
Dividend %- Quick Ratio4.50 Sales past 5Y- Gross Margin- 52W Low50.51% ATR0.31
Employees121 Current Ratio4.50 Sales Q/Q- Oper. Margin- RSI (14)56.21 Volatility10.54% 12.81%
OptionableYes Debt/Eq0.02 EPS Q/Q34.70% Profit Margin- Rel Volume1.39 Prev Close3.03
ShortableYes LT Debt/Eq0.01 Earnings- Payout- Avg Volume340.64K Price2.95
Recom2.70 SMA206.12% SMA5015.22% SMA200-46.36% Volume472,556 Change-2.64%
May-07-20Downgrade Evercore ISI Outperform → In-line
Oct-11-19Initiated Evercore ISI Outperform $22
Aug-29-19Downgrade Citigroup Neutral → Sell $6
Aug-19-19Upgrade SVB Leerink Mkt Perform → Outperform $8 → $15
Aug-16-19Upgrade Chardan Capital Markets Neutral → Buy $7.50 → $10
May-14-19Downgrade Goldman Neutral → Sell $5 → $4
May-14-19Downgrade Credit Suisse Neutral → Underperform $7 → $6
Feb-08-19Upgrade Citigroup Sell → Neutral $8
Feb-08-19Downgrade SVB Leerink Outperform → Mkt Perform
Nov-06-18Initiated Citigroup Sell
Sep-06-18Initiated Credit Suisse Neutral $38
May-29-20 08:35AM  Why Solid Biosciences (SLDB) Stock Might be a Great Pick Zacks
May-22-20 07:00AM  Solid Biosciences to Hold Virtual Annual Meeting of Stockholders on June 16, 2020 GlobeNewswire
May-14-20 07:00AM  Solid Biosciences Presents Data from Duchenne Muscular Dystrophy Gene Therapy Program at ASGCT 23rd Annual Meeting GlobeNewswire
May-13-20 09:49AM  Top Ranked Momentum Stocks to Buy for May 13th Zacks
May-11-20 03:03AM  Solid Biosciences: Keep Your Eyes On The Prize Says Top Analyst SmarterAnalyst
May-09-20 01:48PM  Chardan Capital Sticks to Their Buy Rating for Solid Biosciences Llc
May-07-20 07:22AM  Solid Biosciences Provides Update regarding SGT-001 Phase I/II Clinical Hold on IGNITE DMD GlobeNewswire -14.34%
Apr-16-20 07:00AM  Solid Biosciences Announces Appointment of Ian F. Smith to its Board of Directors GlobeNewswire
Mar-12-20 07:00AM  Solid Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update GlobeNewswire -7.01%
Jan-31-20 05:00AM  Families of rare-disease patients take on drug development, but face uphill battle American City Business Journals
Jan-22-20 11:48AM  New FDA documents shed light on agency's rejection of Sarepta drug American City Business Journals
Jan-10-20 10:08AM  Applied Genetic Stock Up on Favorable Eye Therapy Study Data Zacks -5.15%
Jan-09-20 08:00AM  Solid Biosciences Announces Organizational Changes to Prioritize Development of SGT-001 GlobeNewswire -14.45%
Dec-23-19 10:11AM  Sarepta Signs Gene Therapy Agreement With Roche for $1.15B Zacks
Dec-19-19 06:08PM  Is Solid Biosciences Inc. (SLDB) Going to Burn These Hedge Funds? Insider Monkey
Dec-18-19 08:46AM  Benzinga Pro's Top 5 Stocks To Watch For Wed., Dec. 18, 2019: UPS, MU, EPZM, SLDB, XXII Benzinga -17.40%
08:38AM  Solid Biosciences stock are up on DMD study news MarketWatch
06:30AM  Solid Biosciences Provides Data Update from SGT-001 Development Program GlobeNewswire
Dec-16-19 08:52AM  Options Traders Expect Huge Moves in Solid Biosciences (SLDB) Stock Zacks +8.15%
Dec-13-19 08:55AM  Sarepta's Vyondys 53 Receives FDA Approval for DMD, Stock Up Zacks
Nov-20-19 01:28PM  Hedge Fund Innovator Joseph Edelman Doubles Down on These 3 Biotech Stocks TipRanks
Nov-13-19 03:43PM  Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates Zacks +8.51%
Nov-12-19 05:51PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Solid Biosciences Inc. - SLDB GlobeNewswire -74.36%
04:03PM  Biotech Pops After Rival's Gene Therapy Halted By Regulators Investor's Business Daily
10:56AM  FDA intervenes for 3rd time in Solid Biosciences' Duchenne drug tests American City Business Journals
10:22AM  Solid Biosciences Shares Crash To Record Low After FDA Places Gene Therapy Program On Hold Benzinga
10:15AM  Solid Biosciences Stock Crashes Over Safety Concerns About Its Gene Therapy
07:00AM  Solid Biosciences gene therapy trial put on hold by FDA Reuters
06:45AM  Solid Biosciences Provides SGT-001 Program Update GlobeNewswire
Oct-16-19 08:42AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Solid Biosciences Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire +10.70%
Oct-02-19 07:30AM  Solid Biosciences to Participate in the Chardan 3rd Annual Genetic Medicines Conference GlobeNewswire
Sep-03-19 02:21PM  In expense-laden biotech industry, here are the Mass. startups most in need of cash American City Business Journals
Aug-29-19 11:38AM  Citi: Solid Biosciences Rally Unsupported By Fundamentals Benzinga -7.37%
09:02AM  Sell Solid Biosciences Stock Because Its Muscular Distrophy Drug Is Unlikely to Be Competitive
Aug-27-19 07:23AM  Will Solid Biosciences Continue to Surge Higher? Zacks
Aug-20-19 12:20PM  Sarepta's FDA rejection could have ripple effect in other Duchenne biotechs American City Business Journals
12:02PM  Parents Push One Rare-Disease Drug Through FDA, Not Its Successor Bloomberg
10:03AM  Sarepta Stock Falls as FDA Denies Approval to Golodirsen Zacks
Aug-19-19 03:17PM  Solid Biosciences Stock Surge Ignites Options Activity Schaeffer's Investment Research +5.56%
08:58AM  Solid Biosciences Surges on DMD Gene Therapy Study Amendments Zacks
Aug-16-19 12:15PM  Here's Why Solid Biosciences Is Soaring Today Motley Fool +43.25%
Aug-15-19 02:41PM  Sarepta's Lone Analyst Skeptic Takes On 22 Bulls With Renewed Warnings Bloomberg
Aug-14-19 07:25AM  Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire +23.79%
Aug-08-19 10:33AM  Sarepta (SRPT) Q2 Loss Widens Y/Y, Golodirsen Nears Approval Zacks +7.50%
Jul-26-19 07:25AM  Solid Biosciences Announces $60 Million Private Placement with New and Existing Investors GlobeNewswire +34.41%
Jul-01-19 09:35AM  Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues Zacks -9.04%
09:21AM  Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study Zacks
Jun-28-19 06:51PM  Heres What Hedge Funds Think About Solid Biosciences Inc. (SLDB) Insider Monkey +13.86%
04:28PM  Gene Therapy Battle: Pfizer's Test Results Sent This Biotech Stock Flying Investor's Business Daily
Jun-12-19 04:04PM  Bain's second life sciences fund comes in over $1 billion American City Business Journals +5.25%
Jun-06-19 06:10PM  Vertex enters Duchenne field with $245M buy of Exonics American City Business Journals
May-16-19 03:00PM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Solid Biosciences Inc. (SLDB) GlobeNewswire
10:00AM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Solid Biosciences Inc. (SLDB) ACCESSWIRE
May-14-19 04:27PM  This Biotech Is More Than Its Lead Gene Therapies: Here Are 4 Drugs To Note Investor's Business Daily -28.59%
01:56PM  Solid Bios Plunge Sends a Warning on Gene Therapies Bloomberg
12:26PM  Here's Why Solid Biosciences Fell as Much as 40.9% Today Motley Fool
11:51AM  Solid Biosciences Tanks After Reporting Adverse Event In Duchenne Muscular Dystrophy Trial Benzinga
07:42AM  The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings Benzinga
May-13-19 04:10PM  Solid Biosciences Reports First Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
May-03-19 10:13AM  Heres What Hedge Funds Think About About Solid Biosciences Inc. (SLDB) Insider Monkey
Apr-17-19 11:10AM  Wave Life Sciences Plunges After DMD Study Data Readout Zacks
Apr-16-19 02:39PM  Bain Capital raising another life sciences fund after $720M debut American City Business Journals
Apr-15-19 04:01PM  Solid Biosciences Announces Upcoming Preclinical Data Presentations at The American Society of Gene and Cell Therapy Annual Meeting GlobeNewswire
Apr-08-19 09:45AM  4 Gene Therapy Players Likely to Become Buyout Targets in 2019 Zacks
Mar-28-19 10:20AM  Sarepta plans second Duchenne drug application this year American City Business Journals
Mar-13-19 07:30AM  Solid Biosciences Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update GlobeNewswire
Mar-10-19 10:36AM  10 Stocks For The Gene Therapy Revolution Investopedia
Feb-27-19 09:53AM  The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure Zacks
Feb-26-19 11:15AM  Biotech ETFs Jump on Roche-Spark Deal Zacks
08:54AM  5 Gene Therapy Stocks to Enrich Your Portfolio Zacks
Feb-25-19 03:12PM  Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal Benzinga +9.60%
Feb-20-19 03:52PM  Lifshitz & Miller LLP Announces Investigation of Bristow Group Inc., Helius Medical Technologies, Inc., Nordstrom Inc., PriceSmart, Inc., Ryanair Holdings plc, Solid Biosciences Inc., and Vanda Pharmaceuticals Inc. PR Newswire +6.34%
Feb-15-19 08:56AM  Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review Zacks
Feb-07-19 08:37PM  What Solid Biosciences' First Failure Means for Sarepta Therapeutics Motley Fool -67.82%
04:11PM  Why This Biotech Stock Cratered 68% On Its Gene Therapy Study Investor's Business Daily
01:47PM  A Setback for Solid Is a Win for Sarepta in Race to Treat Muscular Dystrophy
11:22AM  SHAREHOLDER ALERT: Investigation of Solid Biosciences Inc. Announced by Holzer & Holzer, LLC Business Wire
11:05AM  Here's Why Solid Biosciences Plunged Today Motley Fool
10:45AM  Solid Biosciences shares drop 70% on disappointing Duchenne data American City Business Journals
09:42AM  Solid Bio Crashes on Gene Therapy Data as Peer Sarepta Gains Bloomberg
09:25AM  Solid Biosciences stock falls 73% after preliminary Phase 1/2 trial shows efficacy issues with drug MarketWatch
06:45AM  Solid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy GlobeNewswire
Jan-02-19 08:00AM  Solid Biosciences to Present at the J.P. Morgan Healthcare Conference GlobeNewswire +7.91%
Nov-21-18 07:45AM  Research Report Identifies Chicken Soup for the Soul Entertainment, Allied Motion Technologies, Bandwidth, Solid Biosciences, Avenue Therapeutics, and BeyondSpring with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-13-18 07:00AM  Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business Update GlobeNewswire +10.48%
Nov-09-18 07:30AM  Solid Biosciences to Present at the Credit Suisse Healthcare Conference GlobeNewswire -6.39%
Oct-25-18 07:30AM  How This Underfollowed $6 Biotech Could Be Worth $10 ACCESSWIRE
Oct-05-18 04:05PM  Solid Biosciences to Present at the Chardan Genetic Medicines Conference GlobeNewswire
Oct-01-18 08:00AM  Solid Biosciences to Present at the Cell & Gene Meeting on the Mesa GlobeNewswire
Sep-13-18 07:30AM  Solid Biosciences Welcomes Sukumar Nagendran, M.D., To Its Board Of Directors GlobeNewswire -5.33%
Sep-06-18 02:47PM  Credit Suisse Joins Consensus To Prescribe Sarepta Benzinga -9.82%
Aug-30-18 02:00PM  CRISPR without consequences? Startup's drug shows promise in animal study American City Business Journals +5.06%
12:47PM  Scholar Rock stock tumbles 11% as Pfizer discontinues similar medication MarketWatch
Aug-10-18 07:30AM  Solid Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Aug-01-18 10:03AM  Morgan Stanley Buys Into Sarepta Amid Sell-Off, Sees $600M Recurring Opportunity In DMD Candidate Benzinga
Jul-26-18 10:30AM  Sarepta's Clinical Hold Could Be A Solid Biosciences Catalyst, Says Bullish Chardan Analyst Benzinga
Jul-05-18 03:19PM  A Look At IPOs So Far In 2018 Benzinga
Jul-03-18 09:30AM  3 Best Gene Therapy Stocks of 2018 (So Far) Motley Fool +7.87%
Jun-26-18 07:30AM  Solid Biosciences Welcomes Industry Expert Dr. Martin Freed To Its Board Of Directors GlobeNewswire -11.40%
Jun-25-18 08:53AM  Analyst: Solid Biosciences A Solid Buy On Sarepta's Progress Benzinga
Solid Biosciences Inc., a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a monoclonal antibody that is in preclinical trials to reduce fibrosis and inflammation. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits to DMD patients. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.